The primary genetic defect in the Iysosomal storage disease mucolipidosis III (ML III) is in the enzyme uridine diphospho-Nacetylglucosamine:lysosomal enzyme N-acetylglucosamine-lphosphotransferase. This enzyme has two well-defined functions: specific recognition of Iysosomal enzymes (recognition function) and phosphorylation of their oligosaccharides (catalytic function). Using fibroblasts from patients with ML III as the source of enzyme, and a-methylmannoside and two lysosomal enzymes as the substrates, we have identified defects in both of these functions. In one group of fibroblasts, the catalytic activity of the Nacetylglucosaminylphosphotransferase is decreased while the ability to recognize Iysosomal enzymes as specific substrates remains intact. In the second group of fibroblasts, the ability to recognize lysosomal enzymes is impaired while the catalytic ac-
Introduction
Newly synthesized lysosomal enzymes acquire phosphomannosyl residues that allow specific binding to a receptor and selective targeting of these glycoproteins to lysosomes (reviewed in reference 1) . Two enzymes are responsible for generating this marker: uridine diphospho-N-acetylglucosamine (UDPGlcNAc):lysosomal enzyme N-acetylglucosamine-l-phosphotransferase (abbreviated N-acetylglucosaminylphosphotransferase)' and a-N-acetylglucosamine-1-phosphodiester N-acetylglucosaminidase. The first enzyme has been shown to recognize lysosomal enzymes as specific substrates in preference to nonlysosomal glycoproteins (2) (3) (4) . This recognition is mediated by a protein determinant that is shared by many lysosomal enzymes (4) . Based on these data it has been postulated that N-acetyl-1. Abbreviations used in this paper: ML III, mucolipidosis III; N- acetylglucosaminylphosphotransferase, lysosomal enzyme precursor Nacetylglucosamine-I -phosphotransferase; UDP-GlcNAc, uridine di- phospho-N-acetylglucosamine. glucosaminylphosphotransferase contains a catalytic site for mannose phosphorylation as well as a second site that mediates the specific recognition of the common protein determinant of lysosomal enzymes (4) .
Mucolipidosis III (ML III) is characterized by decreased activities of many lysosomal enzymes in connective tissue cells, and by elevated levels of the same enzymes in body fluids (5) . Fibroblasts from patients with ML III have defects in Nacetylglucosaminylphosphotransferase (6) (7) (8) . The most common defect is a decrease in the total catalytic activity of the enzyme. However, a variant (GM339 1) has been described that has normal levels of catalytic activity toward the substrate a-methylmannoside, but an inability to phosphorylate lysosomal enzymes under the conditions tested (7). It was concluded that the defect in this variant enzyme was in its ability to recognize lysosomal enzymes as specific substrates, rather than in its catalytic function. However, no kinetic studies were performed to substantiate this claim. Subsequently, Honey et al. (9) performed cell fusion experiments among different ML III fibroblast lines and found that these lines could be placed into two distinct complementation groups (with the possible existence ofa third group) based on the partial restoration of lysosomal enzyme activities in the heterokaryons. GM3391 was assigned, along with four other ML III fibroblast lines, to one of these complementation groups (designated IIIC), and seven ML III fibroblast lines were assigned to the two other complementation groups (IIIA and IIIB).
The goal of the present study was to determine the kinetic parameters ofN-acetylglucosaminylphosphotransferase from fibroblasts of ML III patients. In particular, we investigated whether the enzyme of complementation group IIIC patients retained any ability to recognize lysosomal enzymes in preference to nonlysosomal glycoproteins and, if so, whether the phosphorylation of all lysosomal enzymes was equally affected. The latter point is significant in terms of trying to understand the structural basis for the common protein determinant of lysosomal enzymes. The second question was whether the mutations in the other patients (presumed, but not proven, to represent complementation groups IIIA and IIIB) solely affected the catalytic activity of the N-acetylglucosaminylphosphotransferase, or if it also affected the ability of this enzyme to recognize lysosomal enzymes. It was felt that these data might provide a biochemical basis for the genetic heterogeneity that has been observed among patients with ML Table I ); A, GM3391 (ML III from group C, Table I ).
N-acetylglucosaminylphosphotransferase. As shown in Table I Though patient T.R. had a lower level of activity, the apparent VMax was actually 80% of the lowest observed normal value, placing it closer to the normal values than to those for the ML III patients described in Table I (ML III group, untested). These three patients have previously been assigned to complementation group IIIC of ML III patients (9) . Each of these fibroblast extracts could phosphorylate both of the lysosomal enzymes, but the affinity for these acceptors was greatly decreased. In two instances it was possible to test concentrations oflysosomal enzymes near the Km, allowing the determination of an apparent Km value of 500 ,M for cathespin D (T.R.) and a value of 244 MM for uteroferrin (T.A.). In both of these cases, the apparent Vmax values As an additional test, the relative catalytic efficiency for ribonuclease B, a nonlysosomal glycoprotein, was determined using GM3391 fibroblasts. A value of 1.9 was obtained, compared with 13 for cathepsin D and 79 for uteroferrin. This provides further evidence that the N-acetylglucosaminylphosphotransferase from complementation group IIIC cell lines has some ability to recognize lysosomal enzymes.
Discussion
The enzyme N-acetylglucosaminylphosphotransferase catalyzes the transfer of N-acetylglucosamine-l-phosphate from UDPGlcNAc to a-linked mannose residues, including a-methylmannoside, high mannose oligosaccharides, and glycoproteins bearing high mannose oligosaccharides (2). The enzyme also functions to specifically recognize some protein determinant common to many lysosomal enzymes, thereby reducing the apparent Km of these glycoproteins to the low micromolar range and allowing their selective phosphorylation (4). These two functions define two distinct sites (or subunits) of the enzyme: a catalytic one and a recognition one. These functionally distinct sites, however, need not be spatially separated.
A deficiency in N-acetylglucosaminylphosphotransferase activity is the primary defect in patients with the lysosomal storage diseases mucolipidosis II and mucolipidosis III (6, 15, 16) .
Fibroblasts from patients with ML II have low or undetectable enzyme levels, whereas fibroblasts from patients with ML III have residual phosphorylating activity (7, 8) , consistent with their milder clinical course (17) . Cell fusion experiments have defined complementation groups among various ML II and ML III fi- Fibroblast extracts of three patients (all from complementation group IIIC) displayed normal or nearly normal kinetic parameters when a-methylmannoside was the acceptor, suggesting the presence of a normal level of the enzyme. In cases where reliable double reciprocal plots could be generated, the level of enzyme activity was also shown to be normal using lysosomal enzymes as the acceptor. However, the affinity for the lysosomal enzymes was significantly decreased. Therefore, these patients appear to contain normal levels of Nacetylglucosaminylphosphotransferase which is defective in its recognition function.
These kinetic data establish two distinct types of biochemical defects in ML III patients, and provide a biochemical basis for the existence of two complementation groups (9) . Since complementation in somatic cells occurs at the protein level, the prior demonstration of at least two complementation groups suggested that the N-acetylglucosaminylphosphotransferase is an oligomeric protein (9, 19 ). While it is not possible to distinguish between an oligomer of identical subunits or one with different, specialized subunits, these data suggest as a working model of the N-acetylglucosaminylphosphotransferase a protein that contains a recognition site (or subunit) and a catalytic site (or subunit), interacting to specifically recognize and phosphorylate lysosomal enzymes. Since complementation studies were not performed with the ML III fibroblasts that have decreased catalytic activity, it is possible that these patients do not fall into the complementation group(s) IIIA (TIIB) of Honey et al. (9) . Nevertheless, it seems extremely likely that they are in a complementation group other than group IIIC.
While the N-acetylglucosaminylphosphotransferase from all three of the group IIIC fibroblast lines exhibited abnormally high Km values for the two lysosomal enzymes, there were differences in the relative affinities for these two substrates. In patient T.A., the apparent Km for uteroferrin was only modestly affected (2.8-fold increase) while the apparent Km for cathepsin D was increased over 12-fold. By comparison, in patient T.R., the Km for cathepsin D was less affected whereas the Km for uteroferrin was more abnormal. This suggests that there may be some "wobble" in the protein recognition marker present on lysosomal enzymes, so that a defect in the recognition site of the N-acetylglucosaminylphosphotransferase could selectively affect recognition of some lysosomal enzymes compared with others. This difference in recognition of various lysosomal enzymes may account for the variable levels of residual lysosomal enzyme activities found in these fibroblasts (9) . It could also contribute to the heterogeneity in the clinical phenotypes ofML III patients.
Of further note are the actual levels of residual activity in fibroblasts from some of the patients described in Table I (ML III group, untested). Obligate heterozygotes have intermediate levels of N-acetylglucosaminylphosphotransferase activity and are clinically unaffected, although they do exhibit increased serum f3-hexosaminidase levels (16) . Some ofthe ML III patients had residual activities as high as 18% of normal, and yet were clearly affected clinically, suggesting that the amount of Nacetylglucosaminylphosphotransferase is quite limiting, at least in some tissues.
